Standout Papers

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor R... 2012 2026 2016 2021 406
  1. AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family (2012)
    Paul R. Gavine, Lorraine Mooney et al. Cancer Research

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 52 standout
Sub-graph 1 of 22

Citing Papers

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout
Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression
2024 Standout
30 intermediate papers

Works of Sarah Beck being referenced

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
2012 Standout
Abstract 3568: Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3
2011

Author Peers

Author Last Decade Papers Cites
Sarah Beck 249 192 53 523 195 30 985
Sebastian Dütting 353 118 89 254 161 18 829
James M. Onoda 163 95 164 300 229 33 788
David Cervi 271 104 32 543 367 21 929
Shiro Koizume 220 126 39 475 165 36 990
Olivier Calvayrac 111 141 29 421 130 23 853
Kevin S. Choe 187 267 2 348 311 31 1000
Tibor Schomber 213 82 89 427 250 18 794
Myriam Maoz 298 74 110 417 177 30 878
Hava Shapiro 194 89 76 243 183 34 796
Lydie Crescence 215 140 46 367 475 31 1.1k

All Works

Loading papers...

Rankless by CCL
2026